Publications
5439 Results
- Journal / Conference
- European Urology Oncology Mar 23:S2588-9311(24)00054-3. doi: 10.1016/j.euo.2024.03.001. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Genitourinary
- PMID
- PMID38523017
- Study Number(s)
- S1216
Three- and seven- month prostate-specific antigen levels as prognostic markers for overall survival in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel or bicalutamide
- Journal / Conference
- Cancer Feb 22. doi: 10.1002/cncr.35264. Online ahead of print
- Year
- 2024
- Research Committee(s)
- Palliative and End of Life Care
- PMID
- PMID38386696
- Study Number(s)
- S1820
SWOG S1820: A Pilot Randomized Trial of the Altering Intake, Managing Bowel Symptoms Intervention in Survivors of Rectal Cancer (AIMS-RC)
- Journal / Conference
- ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA), poster; J Clin Oncol 42, 2024 (suppl 3; abstr 182)
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
- Study Number(s)
- CTSU/C80405
Analysis of immune-related genes (IRGs) and their potential role in sexual dimorphism in metastatic colorectal cancer (mCRC) patients (pts)
- Journal / Conference
- ASCO GU Symposium (JAN 25-27, 2024, San Francisco, CA), poster; J Clin Oncol 42, 2024 (suppl 4; abstr 509)
- Year
- 2024
- Research Committee(s)
- Prevention and Epidemiology
- Study Number(s)
- S1823
North American Patterns of Care in Clinical Stage I Testicular Cancer. Secondary Data Use Project for SWOG S1823
- Journal / Conference
- JCO Oncology Practice Apr;20(4):491-502
- Year
- 2024
- Research Committee(s)
- Cancer Care Delivery
Characteristics of Health Care Settings Where Adolescents and Young Adults Receive Care for ALL
- Journal / Conference
- J Clin Oncol 42, 2024 (suppl 3; abstr TPS430); ASCO GI Cancers Symposium (January 18-20, 2024, San Francisco, CA), TIP, poster
- Year
- 2024
- Research Committee(s)
- Gastrointestinal
SWOG S2303: Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS = 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
- Journal / Conference
- Haematologica Jan 1;108(1):42-47
- Year
- 2023
- Research Committee(s)
- Leukemia
- PMID
- PMID35833298
- PMC
- PMC9827148
- Study Number(s)
- S0106, S1203, SWOG-8600, SWOG-9031
Improved outcomes with 7+3 induction chemotherapy for acute myeloid leukemia over the past four decades: Analysis of SWOG trial data
- Journal / Conference
- Journal of Clinical Oncology 10;41(2):336-342
- Year
- 2023
- Research Committee(s)
- Lymphoma
- PMID
- PMID35787017
- PMC
- PMC9839232
- Study Number(s)
- S0016, S0801
Relevance of bone marrow biopsies for response assessment in U.S. National Cancer Institute National Clinical Trials Network follicular lymphoma clinical trials
- Journal / Conference
- Journal of Clinical Oncology Jan 20;41(3):472-478
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID36067452
- PMC
- PMC9870237
- Study Number(s)
- CTSU/C80405
Acquired Genomic Alterations on First Line Chemotherapy with Cetuximab/Bevacizumab in Advanced Colorectal Cancer: Circulating Tumor DNA Analysis of CALGB/SWOG-80405 Trial
- Journal / Conference
- Annals Surgical Oncology Feb;30(2):1099-1109
- Year
- 2023
- Research Committee(s)
- Gastrointestinal
- PMID
- PMID36305992
- PMC
- PMC9807536